Sage Therapeutics gains on postpartum depression drug briefing docs released

Shares of Sage Therapeutics (SAGE) are up about 1% in early trading after the FDA released briefing documents with background information for the panel members of the advisory committee being called to review the company’s New Drug Application for brexanolone for the treatment of postpartum depression. Sage Therapeutics’ Zulresso will face questions on effectiveness and safety at the committee meeting on Friday. The panel will also be asked to discuss a Risk Evaluation and Mitigation Strategy for the infusion

https://thefly.com/landingPageNews.php?id=2814563